AI Drug Discovery Platforms: An Evaluation Framework

Why Platform Selection Matters

AI drug discovery involves integrating multiple computational methods—structure prediction, binding site analysis, molecular docking, molecular design, and candidate evaluation. The platform infrastructure supporting these methods can significantly affect research productivity, data security, and scientific reproducibility.

Selecting an AI drug discovery platform is not solely a software procurement decision. It affects how research teams work, how proprietary data is protected, and how computational discoveries transition to experimental validation.

Evaluation Dimensions

1. Scientific Scope and Capabilities

Different platforms support different discovery workflows. Key questions to assess:

• Structure prediction: What methods are available? How are confidence scores communicated?
• Binding site analysis: Does the platform support pocket detection, druggability assessment, and site characterization?
• Molecular docking: What docking engines are available? How are scoring functions validated?
• Molecular design: What design modalities are supported—small molecules, peptides, protein binders?
• Workflow integration: Do capabilities connect into coherent discovery workflows, or are they isolated tools?

2. Deployment Architecture

Where and how the platform runs has implications for data governance and operational control:

3. Data Governance and Security

For organizations working with proprietary research data, platform data practices are critical:

• Data residency: Where is data stored? Can storage location be controlled?
• Data isolation: Is organizational data isolated from other customers?
• Access controls: What authentication, authorization, and audit capabilities exist?
• Model training: Is customer data used to train vendor models? Can this be contractually excluded?
• Data retention: What data is retained, for how long, and can it be deleted?

4. Reproducibility and Provenance

Scientific reproducibility requires clear documentation of methods and parameters:

• Method versioning: Are computational methods versioned so results can be reproduced?
• Parameter tracking: Are all parameters that affect results recorded?
• Workflow documentation: Can the complete analytical path be reconstructed?
• Export capabilities: Can results and methods be exported for independent validation?

5. Experimental Handoff

Computational predictions must eventually connect to experimental validation:

• Output formats: Are computational results provided in formats useful for experimental planning?
• Prioritization support: Does the platform help rank candidates for experimental testing?
• Synthesis accessibility: For small molecules, how accessible are predicted compounds?
• Integration points: Does the platform integrate with laboratory information systems or CRO workflows?

Evaluation Process Recommendations

Define Requirements Before Evaluation

Before engaging vendors, internal stakeholders should align on requirements: Which workflows are essential? What data sensitivity constraints exist? What deployment models are acceptable? What reproducibility standards must be met?

Test With Representative Problems

Request access to test the platform with research problems representative of your actual work. Generic demonstrations may not reveal limitations relevant to your specific use cases.

Assess Total Integration Effort

Consider the complete integration effort—not just software licensing. What training is required? How will the platform fit with existing data infrastructure? What ongoing support is needed?

Review Contractual Terms Carefully

For pharmaceutical organizations, contractual terms around data ownership, usage rights, and IP implications deserve careful legal review.